Non-Alcoholic Steatohepatitis (NASH) Epidemiology Analysis and Forecast to 2032

Non-alcoholic steatohepatitis (NASH) is a subtype of non-alcoholic fatty liver disease (NAFLD) that is characterized by liver cell damage and inflammation (Sheka et al., 2020). NASH is often asymptomatic and is detected incidentally. A liver biopsy is required for diagnosis. NASH can occur with or without liver fibrosis and can progress to more serious liver disease. A total of 20% of NASH patients will develop cirrhosis and all NASH patients are at increased risk for hepatocellular carcinoma (Sheka et al., 2020).

Scope

Non-alcoholic steatohepatitis report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for NASH in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiology forecast for the diagnosed prevalent cases of NASH. The diagnosed prevalent cases of NASH are segmented by age and sex. Additionally, the forecast is further segmented based on fibrosis stage and cirrhosis type. This report also provides the historical and 10-year forecasted total and diagnosed prevalent cases of NAFLD.

Reasons to Buy

The NASH Epidemiology series will allow you to -

Develop business strategies by understanding the trends shaping and driving the global NASH markets.
Quantify patient populations in the global NASH markets to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for NASH therapeutics in each of the markets covered.
Understand magnitude of the NASH population by age, sex, fibrosis stage, and cirrhosis type.

Product Code: GDHCER313-23

About GlobalData

1 Non-Alcoholic Steatohepatitis: Executive Summary

1.1 Catalyst
1.2 Related reports
1.3 Upcoming reports

2 Epidemiology

2.1 Disease background
2.2 Risk factors and comorbidities
2.3 Global and historical trends
2.4 7MM forecast methodology
- 2.4.1 Forecast assumptions and methods
- 2.4.2 Forecast assumptions and methods: diagnosed prevalent cases of NAFLD
- 2.4.3 Forecast assumptions and methods: total prevalent cases of NAFLD
- 2.4.4 Forecast assumptions and methods: diagnosed prevalent cases of NASH
- 2.4.5 Forecast assumptions and methods: diagnosed prevalent cases of NASH by fibrosis stage.
- 2.4.6 Forecast assumptions and methods: diagnosed prevalent cases of NASH with compensated and decompensated cirrhosis.
2.5 Epidemiological forecast for non-alcoholic steatohepatitis (2022-32)
- 2.5.1 Diagnosed prevalent cases of NASH.
- 2.5.2 Age-specific diagnosed prevalent cases of NASH
- 2.5.3 Sex-specific diagnosed prevalent cases of NASH
- 2.5.4 Diagnosed prevalent cases of NASH by fibrosis stage.
- 2.5.5 Diagnosed prevalent cases of cirrhosis attributable to NASH.
2.6 Discussion
- 2.6.1 Epidemiological forecast insight
- 2.6.2 Obesity omission
- 2.6.3 COVID-19 impact.
- 2.6.4 Limitations of the analysis
- 2.6.5 Strengths of the analysis

3 Appendix

3.1 Bibliography
3.2 Primary research - high-prescriber survey
3.3 About the Authors
- 3.3.1 Epidemiologist
- 3.3.2 Reviewers
- 3.3.3 Vice President of Disease Intelligence and Epidemiology
Contact Us

Product Code: GDHCER313-23

List of Tables

Table 1: Summary of newly added data types
Table 2: Summary of updated data types
Table 3: Non-alcoholic fatty liver disease activity score
Table 4: Risk factors and comorbidities for CKD
Table 5: High-prescribing physicians (non-KOLs) surveyed, by country

List of Figures

Figure 1: 7MM, diagnosed prevalent cases of NASH, both sexes, N, all ages, 2022 and 2032
Figure 2: 7MM, diagnosed prevalence of NASH, both sexes, %, all ages, 2012-32
Figure 3: 7MM, sources used to forecast the diagnosed prevalent cases of NAFLD
Figure 4: 7MM, sources used to forecast the total prevalent cases of NAFLD
Figure 5: 7MM, sources used to forecast the diagnosed prevalent cases of NASH
Figure 6: 7MM, sources used to forecast diagnosed prevalent cases of NASH by fibrosis stage
Figure 7: 7MM, sources used to forecast the diagnosed prevalent cases of NASH by cirrhosis type
Figure 8: 7MM, diagnosed prevalent cases of NASH, N, men and women, all ages, 2022
Figure 9: 7MM, diagnosed prevalent cases of NASH by age, N, men and women, 2022
Figure 10: 7MM, diagnosed prevalent cases of NASH by sex, N, all ages, 2022
Figure 11: 7MM, diagnosed prevalent cases of NASH by fibrosis stage, N, men and women, all ages, 2022
Figure 12: 7MM, diagnosed prevalent cases of cirrhosis attributable to NASH, N, men and women, all ages, 2022

Non-Alcoholic Steatohepatitis (NASH) Epidemiology Analysis and Forecast to 2032

Description

Table of Contents

List of Tables

Abstract

Scope

Reasons to Buy

Table of Contents

Table of Contents

1 Non-Alcoholic Steatohepatitis: Executive Summary

2 Epidemiology

3 Appendix

List of Tables

List of Tables

List of Figures

List of Figures